Advances in DLL3-targeted therapies for small cell lung cancer
Author Information
Author(s): Ding Jianhua, Yeong Chaihong
Primary Institution: Taylor’s University, Subang Jaya, Selangor, Malaysia
Hypothesis
The review explores the evolving landscape of DLL3-targeted therapies in small cell lung cancer (SCLC), examining their mechanistic basis, preclinical promise, and clinical development.
Conclusion
DLL3-targeted therapies hold the potential to revolutionize treatment paradigms for small cell lung cancer.
Supporting Evidence
- Recent advances in understanding SCLC biology have identified DLL3 as a promising target for novel therapies.
- Emerging bispecific T-cell engagers represent a new frontier in DLL3-directed immunotherapy.
- Current research efforts are focused on harnessing the Notch signaling pathway in SCLC through DLL3-targeted therapies.
Takeaway
This study looks at new treatments for a type of lung cancer that targets a specific protein called DLL3, which could help doctors treat patients better.
Methodology
The review discusses various therapeutic modalities, including antibody-drug conjugates, bispecific T-cell engagers, and chimeric antigen receptor T-cell therapies.
Limitations
The review highlights challenges in translating DLL3-targeted therapies into clinical practice, including setbacks faced by early therapies.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website